Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/6/24 → 5/6/27 |
Funding
- Eli Lilly and Company: $93,754.00
23-LUN-135-EL (J3M-MC-JZQB): A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those with
- Arnold, Susanne M (PI)